Schott Pharma lifts FY outlook after syringe dispute settlement

Schott Pharma raised FY2026 outlook after resolving a glass syringe customer dispute: constant-currency revenue growth guidance lifted to 5%-6% (from 2%-5%) and EBITDA margin to 27%-28% (from ~27%). Preliminary Q3 results showed ~8% constant-currency revenue growth and ~27% EBITDA margin, both ahead of Vara consensus (3.5% growth and 27.5% margin). RBC upgraded the stock to “outperform” with a €21 price target from €18, citing tangible evidence of an inflection.

Analysis

This is primarily a de-risking event, not a pure growth inflection. In medtech packaging, resolution of a customer dispute removes the market’s fear of structural share loss, which usually matters more for the multiple than the near-term EPS delta. The key mechanism is rerating: if investors believe revenue is now stable and margins can hold in the high-20s, the stock should trade less like a cyclical components supplier and more like a durable specialty manufacturing compounder.

Second-order, the settlement should help the broader injectable packaging ecosystem by signaling that downstream demand is still healthy enough to absorb contractual resets. That is constructive for listed peers such as STVN and, to a lesser extent, GXI, because it supports pricing discipline and reduces the odds of a sector-wide volume overhang. The caveat is that any compensation element can flatter near-term growth; if future periods show a normalization cliff, the market will quickly reclassify this as a one-off accounting reset rather than a true operating inflection.

The contrarian risk is that consensus may be underestimating how much of the upside is already in the gap-up and analyst upgrade, while overestimating the durability of the improved revenue run-rate. The 1-3 month catalyst is analyst revisions and a cleaner read on organic demand; the 6-18 month test is whether the business can sustain mid-single-digit growth without relying on settlement carry. Falsifier: the next update shows revenue growth dropping back below mid-single digits once the compensation effect washes out, or margins slipping back under 27%.

Key Decisions for Investors

• Long 1SXP on pullbacks over the next 1-3 weeks; treat the first move as a de-risking gap, not chase strength intraday. Base case is 10-15% rerating if the next print confirms normalized growth; cut if management implies the uplift was mainly settlement-related.
• Pair trade: long 1SXP / short GXI for 1-3 months to express cleaner execution and lower customer-concentration risk versus a broader, more levered packaging peer. This works if the market rewards visibility over headline growth; exit if GXI starts seeing similar guidance revision upside.
• Watchlist alert on STVN for sympathy rerating; buy only if it lags the read-through and then holds after the next sector tape. The trade is a 2-3 quarter multiple expansion bet, with downside if sector order books soften or if Schott’s follow-through disappoints.